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ABSTRACT
Objectives: Statins may decrease the risk of primary
venous thromboembolism (VTE), that is, deep vein
thrombosis (DVT) and pulmonary embolism (PE) but
the effect of statins in preventing recurrent VTE is less
clear. The aim of this study was therefore to investigate
the association between statin therapy and risk of
recurrent VTE.
Design: A prospective cohort study.
Setting: All hospitals in Denmark.
Participants: All patients with a hospital diagnosis of
VTE in Denmark during 1997–2009 associated with a
warfarin or heparin prescription were identified.
Main outcome measures: Adjusted HR of recurrent
hospitalised VTE (ie, fatal or non-fatal DVT or PE)
associated with use of statins.
Results: 44 330 patients with VTE were included in
the study. Of these 3914 were receiving statin therapy
at baseline. Patients receiving statins were older (68±11
compared to 62±18 years), had more comorbidity and
used more medications. The incidence rate for
recurrent VTE was 24.4 (95% CI 22.8 to 26.2) per
1000 person-years among statin users and 48.5 (95%
CI 47.4 to 49.7) per 1000 person-years among non-
statin users. Statin use was associated with a
significantly lower risk of a recurrent VTE, adjusted HR
0.74 (95% CI 0.68 to 0.80), compared with no statin
use. The association between statin use and risk of
recurrent VTE was significantly affected by age. Among
younger individuals (≤80 years), statin use was
associated with lower risk of recurrent VTE, HR 0.70
(95% CI 0.65 to 0.76) whereas in older individuals
(>80 years) statin use was significantly associated with
higher risk of recurrent VTE, HR 1.28 (95% CI 1.02 to
1.60), p for interaction=<0.0001.
Conclusions: Statin use was associated with a
decreased risk of recurrent VTE.
INTRODUCTION
Venous thromboembolism (VTE), that is,
deep vein thrombosis (DVT) and pulmonary
embolism (PE) are common diseases asso-
ciated with high morbidity and mortality.
Primary VTE has an incidence rate of
1–2/1000 person-years in Western popula-
tions1 2 and more than 30% of patients with
VTE experience at least one recurrent episode
during the following 5-year period.3 4 The risk
of VTE is inﬂuenced by many temporary
factors such as surgery,5 cancer and immobil-
isation, but if no such conditions are apparent,
short-term secondary prophylaxis with anticoa-
gulants may be insufﬁcient in order to prevent
recurrent VTE. A ﬁrst episode of unprovoked
VTE is nevertheless followed by 3–6 months of
anticoagulant therapy with vitamin K antago-
nists in order to reduce the risk of recurrent
episodes. The risk of major bleeding is the
foremost complication of treatment and one
of the main reasons for limiting treatment dur-
ation to 3–6 months. Statins have been shown
to be associated with reduced risk of VTE and
may therefore constitute a possible long-term
supplement to antithrombotic treatment after
VTE.6 7 The potential role of statins on the
coagulation system is currently not clear, but
statins may carry an antithrombotic effect by
inhibiting the expression of tissue factor and
thereby inhibit platelet activation.6 8–12 A ran-
domised controlled trial of rosuvastatin in the
primary prevention of VTE, a meta-analysis,
and several observational studies have shown a
signiﬁcant reduction in the risk of VTE asso-
ciated with the use of statins ranging from
20% to 60%.13–20 However, another recent
meta-analysis including unpublished trials
showed no signiﬁcant effect of statins on the
primary risk of VTE.21
Strengths and limitations of this study
▪ We lacked data on chemotherapy, obesity, preg-
nancy and smoking.
▪ The main strength of our study was the large
amount of individuals included.
▪ The main limitation was the observational nature
of the study.
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The effect of statin treatment on prevention of recur-
rent episodes in patients with a previous VTE is insufﬁ-
ciently investigated. Therefore, the aim of our study was
to investigate if statin use could have a preventive effect
on recurrent VTE in a nationwide cohort of patients
with DVT or PE.
METHODS
Data-sources
In Denmark every resident is, at the time of birth or
immigration, provided with a unique and permanent
civil registration number, which enables linkage between
nationwide administrative registers on the individual
level. The Danish National Patient Register was estab-
lished in 1978 and includes information on all hospitali-
sations in Denmark since 1978. At discharge, each
admission is registered with one primary and if appropri-
ate, one or more secondary diagnoses according to the
International Classiﬁcation of Diseases (ICD): the 10th
revision (ICD-10).22 23 The National Register of
Medicinal Product Statistics24 holds data on every dis-
pensed prescription from pharmacies in Denmark since
1995. Dispensed drugs are registered by the inter-
national Anatomical Therapeutic Classiﬁcation (ATC)
system along with information on date and amount dis-
pensed. Information on vital status was obtained from
the Danish Civil Registry25 and causes of death from the
Danish Registry of Causes of Death.26
Study population
All patients with a hospital diagnosis of VTE between
1 January 1997 and 31 December 2009 (in patients and
out patients) were identiﬁed. The VTE diagnoses com-
prised the following ICD-10 codes: I26 (pulmonary embol-
ism), I80 (phlebitis and thrombophlebitis) and I82 (other
venous embolism and thrombosis). Patients with any of
I82.0 (Budd-Chiari syndrome), I80.0 (phlebitis and
thrombophlebitis of superﬁcial vessels of lower extrem-
ities) and I80.8 (phlebitis and thrombophlebitis of other
sites) were excluded. To ensure a correct diagnosis of VTE
we required that a diagnosis of VTE was followed by appro-
priate anticoagulation therapy and therefore excluded
patients who did not claim a prescription of anticoagula-
tion therapy from a pharmacy (heparin or warfarin/mar-
coumar) within 30 days of the diagnosis of VTE. The
follow-up time started 90 days after the inpatient admis-
sion date (index date), which we assumed as the date of
VTE, and patients were followed until the ﬁrst occurrence
of any of the following: hospitalisation with VTE diagnoses,
emigration, death or 31 December 2009. The reason for
starting follow-up 90 days after the hospital admission date
was to avoid including any workup investigations related to
the initial VTE event.
Comorbidity
Comorbidity was deﬁned by hospitalisation diagnoses up
to 1 year prior VTE diagnosis. The concomitant
diagnoses (ICD-10 codes) of interest were ischaemic
heart disease (I20, I23–I25), acute myocardial infarction
(I21–I22), atrial ﬂutter/ﬁbrillation (I48), peripheral vas-
cular disease (I70–I74), diabetes mellitus (E10–E14) and
malignancies (C00–C97).
Pharmacotherapy
Use of the following drugs was identiﬁed: statins (ATC
code C10AA), glucose-lowering medications (A10), non-
steroidal anti-inﬂammatory drugs (NSAIDs) (M01),
hormone replacement therapy/oral contraceptives (G03),
diuretics (C03), low-dose aspirin (B01AC06), clopidogrel
(B01AC04), ACE inhibitor/angiotensin II antagonist
(C09) and antipsychotics (N05A). Patients were deﬁned as
users at baseline if the prescription was redeemed 90 days
before or 90 days after the index date. Patients were
allowed to initiate and discontinue medications through-
out follow-up and hence change exposure status during
the study period.
The exposure status was updated approximately every
90 days. The daily dosage of medication is not recorded
in the national prescription register. Treatment with
vitamin K antagonists (B01AA) and statins were assessed
for each day by considering the amount of claimed med-
ications and claiming time interval for up to three con-
secutive prescriptions. On the basis of these
assumptions, we calculated whether patients at any time
had tablets available or not. Patients were considered
exposed only while taking the medications. This method
is described in more detail elsewhere.27 The minimal
dose of warfarin is 1.25 mg and maximal dose is 10 mg.
Minimal dose of simvastatin, lovastatin, pravastatin, ﬂu-
vastatin, atorvastatin and rosuvastatin are 5, 10, 10, 20,
10 and 5 mg, respectively. The maximal dose is 80 mg
for all subtypes of statins. The cut-off points for high
dosage of simvastatin, lovastatin, pravastatin, ﬂuvastatin
and atorvastatin were 20 mg and for rosuvastatin the
cut-off point was 10 mg.
Surgery
From The Danish National Patient Register we obtained
information on cardiovascular surgery, abdominal
surgery and orthopaedic surgery to adjust for the risk of
VTE associated with surgery in the multivariate regres-
sion analysis. Surgery was included as a time-varying cov-
ariate in the models and patients were considered
exposed 30 days following the date of surgery.
Study outcome
A recurrent VTE was deﬁned as a new inpatient or out-
patient admission with the diagnosis of VTE (ICD-10
codes I26, I80 or I82, except I82.0, I80.0 and I80.8,
which were excluded) together with a claimed prescrip-
tion of anticoagulants (heparin or vitamin K antago-
nists) within 30 days before or after the diagnosis, or
VTE coded as the primary or contributing cause of
death in the death certiﬁcate (same ICD-codes as
above). For the composite endpoint, VTE and individual
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endpoints, patients with DVT or PE, were followed until
the ﬁrst recurrent event of the type of interest, emigra-
tion, death or end of study (31 December 2009).
Statistical analysis
Discrete variables were compared using χ2 test and con-
tinuous variables were compared using the t test. We
also calculated crude incidence rates for recurrent DVT,
PE and VTE as numbers of events/1000 person-years.
Multivariable Cox proportional hazard regression
models were used to estimate HR for the recurrent DVT,
PE and VTE associated with individual risk factors. All
models included age, sex, ischaemic heart disease, acute
myocardial infarction, atrial ﬂutter/ﬁbrillation, periph-
eral vascular disease, diabetes mellitus, malignancies,
statins, warfarin, low-dose aspirin, clopidogrel, hormone
replacement therapy/oral contraceptives, glucose-
lowering medications, diuretics, NSAIDs, ACEi/ARB,
antipsychotic medications and surgery. In all models,
medications and surgery were time-dependent variables,
meaning that patients were only considered exposed
when they were taking the drugs or 30 days following
the date of surgery. Model assumptions—the linearity of
continuous variables, the proportional hazards assump-
tion and lack of interactions—were tested and found
valid unless otherwise indicated. Tests for interactions
(between statin and the different variables) were
performed by inclusion of an interaction term in the
analysis.
All calculations were performed using SAS V.9.2 (SAS
Institute, Cary, North Carolina, USA). A p value <0.05
was regarded statistically signiﬁcant. Adjusted numbers
needed to treat were calculated by using the methods
described by Bender et al.28
RESULTS
A total of 44 330 patients with VTE were included in the
study. Of these 3914 (9.7%) received statin therapy and
40 416 did not receive statin therapy at study baseline.
The mean follow-up time was 1438 days for the entire
study population. In total 225 patients emigrated during
follow-up. The baseline characteristics of statin users and
non-statin users are presented in table 1. More patients
initiated statin therapy during follow-up and altogether
9869 patients received statin therapy in our study at
some point in time. At baseline the majority (81%) of
statin users were treated with simvastatin (table 2).
Patients with statin therapy were older (68±11 compared
to 62±18 years), had more concomitant diseases such as
diabetes mellitus (15% vs 4%) and peripheral artery
disease (7% vs 2%) and used more medications, particu-
larly low-dose aspirin (50% vs 13%), ACEi/ARB (50% vs
15%) and glucose-lowering drug (20% vs 5%), com-
pared to patients without statin therapy.
Table 1 Baseline characteristic
Characteristic No statin therapy (N=40 416) Statin therapy (N=3914)
Age (years)—n (%)
≤50 10 278 (25) 264 (7)
51–60 6623 (16) 575 (15)
61–70 8187 (20) 1190 (30)
71–80 8636 (21) 1304 (33)
>80 6692 (17) 581 (15)
Age, mean(±SD), years 62.1 (±17.7) 68.4 (±11.3)
Women—n (%) 20 816 (52) 1810 (46)
Concomitant diseases*—n (%)
Ischaemic heart disease 1639 (4) 868 (22)
Acute myocardial infarction 343 (1) 249 (6)
Atrial flutter/fibrillation 2196 (5) 375 (10)
Peripheral artery disease 828 (2) 270 (7)
Diabetes mellitus 1628 (4) 605 (15)
Malignancies 3903 (10) 346 (9)
Concomitant medications†—n (%)
Low-dose aspirin 5440 (13) 1954 (50)
Clopidogrel 163 (0.4) 276 (7)
Hormone replacement therapy 5281 (13) 335 (9)
ACEi/ARB 6037 (15) 1939 (50)
Glucose-lowering medications 1905 (5) 800 (20)
Diuretics 13 362 (33) 2140 (55)
Antipsychotic medication 2376 (6) 190 (5)
Nonsteroidal anti-inflammatory drugs 10 223 (25) 989 (25)
*Concomitant diseases refer to hospitalisation diagnosis (ICD 10-codes) up to 1 year prior to venous thromboembolism (VTE) hospitalisation.
†Concomitant medications refer to claimed prescription of an agent in the period between 90 days before to hospitalisation and 90 days after
first hospitalisation date.
ACEi/ARB, ACE inhibitor/angiotensin II antagonist.
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Association between statins and risk of recurrent VTE
The median follow-up time was 1078 days (IQR 361–
2271 days) for the entire population, 423 days (IQR
121–1127 days) for those with recurrent VTE and
1285 days (IQR 491–2494 days) for those without recur-
rent VTE. Recurrent VTE occurred in 8264 (18%)
patients, of which 5320 had a recurrent DVT and 3744
had a recurrent PE. The incidence rate of recurrent
VTE, DVT and PE are presented in table 3.
For the VTE endpoint statin use was associated with a
lower risk of a recurrent VTE, unadjusted HR 0.75 (95%
CI 0.70 to 0.81; table 4), adjusted for age and sex, HR
0.74 (95% CI 0.68 to 0.79) and adjusted for all variables,
HR 0.74 (95% CI 0.68 to 0.80). A signiﬁcant interaction
was seen between statins and age, p≤0.0001. Statins were
associated with a substantially lower risk of recurrent
VTE among younger patients, compared with older
patients. A signiﬁcant interaction was also seen between
statins and gender, p≤0.0001. Statin use was associated
with lower HR in men, compared with women, HR 0.65
(95% CI 0.59 to 0.72) vs HR 0.87 (95% CI 0.78 to 0.98).
Further, a signiﬁcant interaction was also found between
statin use and low-dose aspirin, p=0.03. Statin use was
associated with signiﬁcantly lower HR of VTE if adminis-
tered without low-dose aspirin than if administered with
low-dose aspirin, HR 0.70 (95% CI 0.63 to 0.76) com-
pared to 0.82 (95% CI 0.72 to 0.93).
Analysing each endpoint separately, we found that
statin use was associated with signiﬁcantly lower risk of a
recurrent DVT, HR 0.66 (95% CI 0.59 to 0.71), as well as
recurrent PE, HR 0.87 (95% CI 0.78 to 0.97), compared
to no statin use (table 4). The adjusted numbers needed
to treat among statin users were 79 for VTE, 392 for PE
and 97 for DVT.
A dose–response analysis revealed no signiﬁcant differ-
ential association between low-dose statin use, HR 0.76
(95% CI 0.68 to 0.85) and high-dose statin use, HR 0.71
(95% CI 0.64 to 0.79) on the risk of a recurrent VTE.
DISCUSSION
In our nationwide study comprising over 40 000 patients
with prior VTE, statin use was associated with a signiﬁ-
cant reduction in the occurrence of recurrent VTE. This
was found for recurrent DVT as well as for recurrent PE.
This is the ﬁrst study to evaluate the VTE-prophylactic
Table 2 Type of statin used at baseline
n Per cent
Any statin expose 3911
Simvastatin 3185 81.4
Lovastatin 54 1.4
Pravastatin 208 5.3
Fluvastatin 43 1.1
Atorvastatin 377 9.6
Rosuvastatin 81 2.1
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effect of statin among participants with previous VTE on
such a large population. Whether statins can be used as
prophylaxis in patients with a previous VTE is an upcom-
ing discussion. To our knowledge, two previous observa-
tional studies have focused on the inﬂuence of statins
on the risk of recurrent thromboembolic events.
Biere-Raﬁ et al recently used a Dutch population-based
registry of pharmacy records linked with hospital dis-
charge records and found that among 3039 patients
with PE statin use was associated with decreased risk of
recurrent pulmonary embolism (HR 0.50 (95% CI 0.36
to 0.70)).29 Delluc et al investigated the association
between statin use and recurrent VTE on a small popu-
lation of 432 participants and found no association.30
There are six subtypes of statins available on the
market and it has not been clear if any reduction of
VTE should be a class effect of statins or if it may differ
between agents. In our study 80% of statin users were
treated with simvastatin. We could therefore not explore
a potential difference in effects between statins.
However, a previous case–control study by Ramacharan
et al,19 with 4538 cases of ﬁrst time VTE, veriﬁed by scan-
ning and with the case’s partners as controls, found that
simvastatin, pravastatin and atorvastin were associated
with lower risk of VTE. Doggens et al16 found simvastatin
to reduce the risk of VTE, but they were unable to ﬁnd
the same association for pravastatin. The recent study by
Biere-Raﬁ et al showed that statins with the strongest
potency, that is, atorvastatin and rosuvastatin, were asso-
ciated with the greatest protection against a recurrent
PE. In our study, however, we could not conﬁrm such a
differential association nor could we identify a dose–
response relation between statin dosages and the risk of
VTE. The lack of dose–response relationship may be
explained by the fact that the maximum effect of statins
on the risk of VTE is reached already at low dose of
statins. Further studies are warranted to investigate this
subject.
We found an interesting modiﬁcation of the effects
associated with statins as dependent on age, and the
antithrombotic effect of statins seemed to decrease with
increasing age. Statin use among patients over 80 years
of age was not signiﬁcantly associated with a lower risk of
recurrent VTE. Notably, increasing age in itself seemed
to be protective against a recurrent VTE in our study. An
explanation for the limited effect associated with statins
in elderly patients could therefore be due to a lower
baseline risk of VTE among elderly, compared with
younger individuals. Another reason could be that
patients over 80 have lower exposure to statins, by being
less likely to be prescribed with statins, as seen in table
1, or had lower compliance compared to those under
80. However, lower compliance is not likely to be a
major reason, since a previous study has shown that
elderly patients had better compliance with statins com-
pared to younger patients.31
Interestingly, a recent randomised study, Aspirin for
preventing the recurrence of venous thromboembolism
(WARFASA) study, found that aspirin was effective in
preventing unprovoked recurrent VTE after discontinu-
ation of vitamin K antagonists.32 We investigated if
adding statins to low-dose aspirin may be effective in
reducing the risk further and we found that, although to
a signiﬁcantly less degree, statins were associated with
lowered risks of VTE also among patients receiving
aspirin. Further, our data suggest that statins may be as
effective as aspirin in preventing VTE in patients with
prior VTE and because they carry a lower risk of bleed-
ing they may constitute an attractive alternative to
aspirin in some patients. Ultimately, a randomised trial
investigating the effect of aspirin, statin and the combin-
ation of the two agents for secondary prophylaxis after
VTE should therefore be performed.
The exact mechanism underlying any protective
effects of statins on risk of VTE is unknown. Some
believe statins may carry an antithrombotic effect by
inhibiting the expression of tissue factor and thereby
inhibiting platelet activation.6 8–12 Others have earlier
suggested that the effect of statin beside the cholesterol
lowering effect is due to ‘healthy user effect’.33 34 Thus,
persons who receive treatment with statins have a health-
ier lifestyle or/and a lower risk proﬁle. In our popula-
tion we cannot rule out a ‘healthy user effect’, although
a recent Danish paper suggested that statin users do not
have healthier lifestyle compare with non-statin users.35
Strengths and limitations
The main strength of our study was the large amount of
individuals included. The Danish National Patient
Registry, as well as the National Prescription Registry
have proven to be accurate in other settings36 37 and the
validity of the inpatient diagnoses of VTE has been
investigated by Severinsen et al, who found a positive pre-
dictive value of 75% (95% CI 71.9% to 77.9%).38 The
Table 4 HRs of venous thromboembolism associated with statin use
Outcome Unadjusted HR (95% CI) Adjusted* HR (95% CI) Adjusted† HR (95% CI)
Venous thromboembolism 0.75 (0.70 to 0.81) 0.74 (0.68 to 0.79) 0.74 (0.68 to 0.80)
Deep venous thrombosis 0.61 (0.55 to 0.67) 0.63 (0.57 to 0.70) 0.66 (0.59 to 0.71)
Pulmonary embolism 0.93 (0.84 to 1.04) 0.86 (0.77 to 0.95) 0.87 (0.78 to 0.97)
*Adjusted for gender and age.
†Adjusted for gender, age, low-dose aspirin, clopidogrel, surgery, ischaemic heart disease, acute myocardial infarction, atrial flutter/fibrillation,
peripheral vascular disease, diabetes mellitus, malignancies, hormone replacement therapy, diuretics, glucose-lowering medication, ACE
inhibitors/angiotensin II antagonists, non-steroidal anti-inflammatory drugs (NSAID) and antipsychotic medication.
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validity of outpatient diagnoses is unknown. To increase
the likelihood of a correct VTE diagnosis we therefore
only included patients with VTE diagnoses together with
redemption of a prescription of anticoagulants (heparin
or warfarin/marcoumar). Still we cannot exclude that
the initial diagnosis of VTE was not in error because of
the presence of other diseases (cellulitis, arthritis) mim-
icking VTE. Also statin users could have been taking
dietary supplements or other over-the-counter medica-
tions not available in the records. These might have
inﬂuenced the VTE recurrence rate.
The main limitation was the observational nature of
the study. We tried to identify the most important risk
factors for VTE and adjusted for them in our multivari-
able analyses. However, we lacked data on, for example,
chemotherapy, obesity, pregnancy and recent trauma,
which may have inﬂuenced our results. Unfortunately,
we also lacked access to data on smoking. However, a
meta-analysis from Circulation39 indicates that smoking
does not increase the risk of VTE. But smokers are less
likely to be exposed to statins.40 Smoking could have
confounded our results and have led to overestimating
the effect of statin use on the risk of VTE. Smoking is a
well-known cardiovascular risk factor and by adjusting
our analyses with cardiovascular diseases and cardiovas-
cular medications we have tried to minimise the con-
founding effects of smoking on our results. Finally,
low-dose aspirin and NSAIDs are available as
over-the-counter medications; hence some patients may
have been misclassiﬁed as non-users. The amount of
over-the-counter low-dose aspirin in Denmark is prob-
ably low since low-dose aspirin, which is used almost
exclusively for secondary prevention of cardiovascular
disease, is generally prescribed by physicians, being reim-
bursable by up to 85% through the National Health
Insurance Programme.
The observational nature of our study makes it difﬁ-
cult to draw a deﬁnite conclusion on whether or not
statins lower the risk of recurrent VTE, but our results
indicate that statins could prevent recurrent episodes of
VTE.
CONCLUSION
In our study with over 40 000 patients with a previous
VTE, we found that the use of statins was associated with
signiﬁcantly lowered risk of a recurrent VTE compared
to no use of statins. Further studies on the effect of
statins on prevention of recurrent VTE episodes are war-
ranted. In particular a randomised clinical trial investi-
gating the effect of statins on the recurrence of VTE is
needed to establish the effect of statins in this clinical
context.
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